Page last updated: 2024-12-08

desmethyltrimipramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

desmethyltrimipramine: major metabolite of trimipramine; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID160632
MeSH IDM0120848

Synonyms (26)

Synonym
nortrimipramine
FT-0665751
2293-21-2
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,2-dimethylpropan-1-amine
desmethyltrimipramine
unii-i453qu04o6
i453qu04o6 ,
5h-dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-n,beta-dimethyl-
n-demethyl trimipramine
n-desmethyltrimipramine
monodemethyltrimiprimine
monodesmethyltrimipramine
trimipramine maleate impurity b [ep impurity]
5h-dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-n,.beta.-dimethyl-
n-desmethyltrimipramine, (rs)-
trimipramine maleate impurity, desmethyltrimipramine- [usp impurity]
FUEUKSCRQNPXKS-UHFFFAOYSA-N
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,2-dimethyl-1-propanamine #
BS-47086
Q27280397
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,2-dimethylpropan-1-amine
DTXSID70945611
STARBLD0004854
n-desmethyltrimipramine,1.0mg/mlinmethanol
F74295
AKOS040759682

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The mean plasma half-life and AUC of amitriptyline oxide and its metabolites were significantly higher in patients than in healthy adults."( [Comparative study of the pharmacokinetics of amitriptyline oxide and trimipramine after single administration in healthy male probands and patients with renal failure].
Degen, J; Fischer, W; Höxter, G; Pintar, P; Seiberling, M; Steinhauer, HB; Wölke, E, 1993
)
0.29

Bioavailability

ExcerptReferenceRelevance
" Absolute bioavailability was 41."( Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection.
Abernethy, DR; Greenblatt, DJ; Shader, RI, 1984
)
0.27
" However, the effect of CYP2D6 genotype on steady state kinetics and on bioavailability has not been studied so far."( Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.
Brockmöller, J; Kirchheiner, J; Meineke, I; Roots, I; Sasse, J, 2003
)
0.32
"Both bioavailability and systemic clearance significantly depended on CYP2D6 genotype with a linear gene dose relationship."( Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.
Brockmöller, J; Kirchheiner, J; Meineke, I; Roots, I; Sasse, J, 2003
)
0.32
"High bioavailability combined with low systemic clearance of trimipramine in poor metabolizers of CYP2D6 substrates results in a very high exposure to trimipramine with the risk of adverse drug reactions."( Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.
Brockmöller, J; Kirchheiner, J; Meineke, I; Roots, I; Sasse, J, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (30.00)18.7374
1990's6 (60.00)18.2507
2000's1 (10.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.82 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (18.18%)4.05%
Observational0 (0.00%)0.25%
Other8 (72.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]